Evidence map›Paper›PMID 37519818›Full record

ArticleFrontiers in oncology2023

An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy.

Maria Colomba Comes, Francesca Arezzo, Gennaro Cormio, Samantha Bove, Angela Calabrese, Annarita Fanizzi, Anila Kardhashi, Daniele La Forgia, Francesco Legge, Isabella Romagno and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Maria Colomba ComesStruttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Francesca ArezzoDipartimento di Medicina di Precisione e Rigenerativa e Area Jonica - (DiMePRe-J), Università di Bari "Aldo Moro", Bari, Italy.
Gennaro CormioGinecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Samantha BoveStruttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Angela CalabreseUnità Operativa Semplice di Radiodiagnostica Avanzata, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Annarita FanizziStruttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Anila KardhashiGinecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Daniele La ForgiaStruttura Semplice Dipartimentale di Radiologia Senologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Francesco LeggeUnità di Ginecologia Oncologica, "F. Miulli" Ospedale Generale Regionale, Acquaviva delle Fonti, Bari, Italy.
Isabella RomagnoUniversità di Bari "Aldo Moro", Bari, Italy.
Vera LoizziGinecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Raffaella MassafraStruttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Tumori Bari · ITUniversity of Bari Aldo Moro · ITOspedale Generale Regionale Francesco Miulli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: It has been estimated that 19,880 new cases of ovarian cancer had been diagnosed in 2022. Most epithelial ovarian cancer are sporadic, while in 15%-25% of cases, there is evidence of a familial or inherited component. Approximately 20%-25% of high-grade serous carcinoma cases are caused by germline mutations in the BRCA1 and BRCA2 genes. However, owing to a lack of effective early detection methods, women with BRCA mutations are recommended to undergo bilateral risk-reducing salpingo-oophorectomy (RRSO) after childbearing. Determining the right timing for this procedure is a difficult decision. It is crucial to find a clinical signature to identify high-risk BRCA-mutated patients and determine the appropriate timing for performing RRSO. Methods: In this work, clinical data referred to a cohort of 184 patients, of whom 7.6% were affected by adnexal tumors including invasive carcinomas and intraepithelial lesions after RSSO has been analyzed. Thus, we proposed an explainable machine learning (ML) ensemble approach using clinical data commonly collected in clinical practice to early identify BRCA-mutated patients at high risk of ovarian cancer and consequentially establish the correct timing for RRSO. Results: The ensemble model was able to handle imbalanced data achieving an accuracy value of 83.2%, a specificity value of 85.3%, a sensitivity value of 57.1%, a G-mean value of 69.8%, and an AUC value of 71.1%. Discussion: In agreement with the promising results achieved, the application of suitable ML techniques could play a key role in the definition of a BRCA-mutated patient-centric clinical signature for ovarian cancer risk and consequently personalize the management of these patients. As far as we know, this is the first work addressing this task from an ML perspective.

Indexed as

BRCA-mutationearly identificationmachine learningovarian cancerrisk-reducing salpingo-oophorectomy

Identifiers

PMID37519818
PMCPMC10374844
OpenAlexW4384300555

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.